Article Details
Retrieved on: 2022-09-06 22:59:08
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
NeuBase is using a proprietary drug discovery platform—the Peptide-nucleic acid AnTisense OLigonucleotide (PATrOL) platform—to develop a class of ...
Article found on: www.genengnews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here